Tourmaline Bio Inc. (TRML)
13.09
-0.31 (-2.31%)
At close: Apr 03, 2025, 3:59 PM
13.24
1.13%
Pre-market: Apr 04, 2025, 04:36 AM EDT
-2.31% (1D)
| Bid | 12.56 |
| Market Cap | 336.22M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -2.89 |
| PE Ratio (ttm) | -4.53 |
| Forward PE | -4.67 |
| Analyst | Buy |
| Ask | 13.74 |
| Volume | 530,042 |
| Avg. Volume (20D) | 319,513 |
| Open | 13.00 |
| Previous Close | 13.40 |
| Day's Range | 12.56 - 13.52 |
| 52-Week Range | 11.87 - 29.79 |
| Beta | 2.16 |
About TRML
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York....
Industry Biotechnology
Sector Healthcare
IPO Date May 7, 2021
Employees 74
Stock Exchange NASDAQ
Ticker Symbol TRML
Website https://www.tourmalinebio.com
Analyst Forecast
According to 6 analyst ratings, the average rating for TRML stock is "Buy." The 12-month stock price forecast is $50, which is an increase of 281.97% from the latest price.
Stock Forecasts3 weeks ago
+10.33%
Tourmaline Bio shares are trading higher on possib...
Unlock content with
Pro Subscription
4 weeks ago
+11.09%
Tourmaline Bio shares are trading higher after Wedbush initiated coverage on the stock with an Outperform rating and announced a price target of $42.
5 months ago · seekingalpha.com
Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 TargetingTourmaline Bio's Pacibekitug shows promise in treating thyroid eye disease, with pivotal phase 2b data expected in 2025 and a phase 3 study starting in 2024. The 7 major thyroid eye disease markets ar...